Zimbabwe has rejected a substantial American health deal worth $367m (£272m) spanning five years over Washington's request for sensitive biological samples.
This move was revealed after a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
An official spokesman has since stated that the United States was requesting biological samples for research and profit while was not willing to guarantee the benefits from any future vaccines.
"We must now begin the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for further dialogue to find a agreement acceptable to all parties so the country's critical HIV treatment initiative can continue.
Broader Context
This development follows a comparable case in neighbouring Kenya, where a high court halted a similar deal with the US following concerns were raised about the security of Kenyans' medical information.
Since returning to the presidency last year, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government agreements to boost transparency and responsibility.
Based on reports, Sixteen African countries have to date agreed to these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy via American-funded initiatives," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to share its biological resources and data indefinitely, with no corresponding promise of access to any medical innovations – like new medicines or tests – that might be developed from that provided information," his statement read.
"Effectively, our country would supply the basic resources for scientific discovery without any assurance that the resulting innovations would be accessible to our people if a new disease outbreak arise."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were undermining frameworks already set up through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This mechanism is designed to guarantee that when a country provides its information, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the resources to develop them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to ongoing discussions with our US partners on how future collaboration could be arranged in a way that respects the sovereignty and dignity of each country."
Medical Community Reaction
Medical experts stated it acknowledged the official position, but suggested that negotiations need to persist given that a large portion of the country's HIV programmes depended on foreign aid.
"If technical issues exist, such as those involving data governance or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," it said.
The situation emphasises the continuing challenges between accepting vital international aid and safeguarding national sovereignty in an increasingly data-driven world.